Miro Sciences (ASX: MSX): Positive Clinical Results and FDA Feedback Support Phase 2 Plans
Nov 8, 2026
Proactive Equities Team
Miro Sciences is advancing its StemSmart™ therapy for treatment-resistant Crohn’s disease, following positive clinical results and favourable FDA feedback. This report examines key developments, clinical milestones, financial risks, share price performance and technical outlook for MSX.